An Open Label, 1-Year Trial, including a Double-Blind Placebo-Controlled Withdrawal Period, of Setmelanotide (RM-493), a Melanocortin 4 Receptor (MC4R) Agonist, in Early Onset Leptin Receptor (LEPR) Deficiency Obesity due to Bi-Allelic Loss-of-Function LEPR Genetic mutations
Active, not recruitingNL-OMON48914
RHYTHM pharmaceuticalsgenetic mutation
Obesity
Start: 2018-03-05Target: 3Updated: 2024-02-28